Disease index

chronic hepatitis B

Hepatology · 2005–2017

16decisions
6medicines
1carried consumer input
0individual submissions

Every decision

MedicineMeetingOutcomeConsumer input
tenofovir alafenamide Treatment of chronic hepatitis B infections in adult patients who are treatment-naïve or treatment-experienced, with or without cirrhosis. Mar 2017 Recommended with restriction input received
tenofovir disoproxil fumarate Treatment of chronic hepatitis B in nucleoside analogue naïve and treatment-experienced patients, as per the TGA indication. Jul 2009 Recommended with restriction no section in document
telbivudine Treatment of chronic hepatitis B in patients who are nucleoside analogue naïve and hepatitis B antigen (HBeAg)-positive with compensated liver disease,… Mar 2008 Recommended with restriction no section in document
tenofovir disoproxil fumarate Extension of listing to include treatment of chronic hepatitis B (CHB) in treatment-naïve patients and nucleos(t)ide-experienced patients. Nov 2008 Recommended with restriction no section in document
telbivudine Treatment of patients with chronic hepatitis B who are nucleoside analogue naïve, with evidence of viral replication and active liver inflammation. Jul 2007 Not recommended no section in document
adefovir dipivoxil Treatment in combination with lamivudine of patients with active chronic hepatitis B who have advanced liver disease (evidence of cirrhosis on liver biopsy or… Mar 2007 Recommended no section in document
adefovir dipivoxil Chronic hepatitis B in patients who have failed antihepadnaviral therapy, with the ability to use adefovir in combination with lamivudine in… Nov 2007 Recommended with restriction no section in document
adefovir dipivoxil Chronic hepatitis B in patients who have failed antihepadnaviral therapy, now with the addition of concurrent use with lamivudine in lamivudine-resistant… Nov 2007 Recommended with restriction no section in document
telbivudine treatment of patients with chronic hepatitis B who satisfy certain criteria, including HBeAg-positive and HBeAg-negative patients with compensated liver… 2007 Not recommended no section in document
adefovir dipivoxil Treatment in combination with lamivudine of nucleoside therapy naïve patients with advanced liver disease, and liver transplant patients with a history of HBV… Jul 2006 Not recommended no section in document
adefovir dipivoxil Treatment in combination with lamivudine for nucleos(t)ide therapy naïve patients with advanced liver disease, and liver transplant patients with a history of… Jul 2006 Not recommended no section in document
adefovir dipivoxil Extension of listing for patients with active chronic hepatitis B to include treatment in combination with lamivudine of nucleoside therapy naïve patients with… Jul 2006 Not recommended no section in document
entecavir Treatment of chronic hepatitis B in adults 16 years and older with evidence of active liver inflammation. Listing sought for nucleoside-naive patients (500… Jul 2006 Recommended with restriction no section in document
entecavir For the treatment of chronic hepatitis B infection in nucleos(t)ide naïve patients and lamivudine resistant patients. 2006 Recommended with restriction no section in document
peginterferon alfa-2a treatment of chronic hepatitis B in patients with compensated liver disease who satisfy certain criteria Nov 2005 Recommended with restriction no section in document
peginterferon alfa-2a Treatment of chronic hepatitis B in adult patients with compensated liver disease, evidence of viral replication and liver inflammation (HBeAg-positive or… Nov 2005 Recommended with restriction no section in document

Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.